Related Experiment Video
Updated: Mar 28, 2026
Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays
Published on: February 24, 2023
Leveraging DNA repair deficiency in gynecologic oncology
Christine S Walsh1, Melissa Hodeib
1Department of Obstetrics and Gynecology, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Purpose Of Review:
The review discusses DNA repair deficiencies in ovarian cancer and how this has become the target for poly (ADP-ribose) polymerase (PARP) inhibition as a successful therapeutic strategy.
Recent Findings:
Hereditary ovarian cancers arise from germline mutations in BRCA1, BRCA2, or other important genes in the DNA repair process of homologous recombination. Sporadic ovarian cancers can also acquire a phenotype of homologous recombination deficiency through various other mechanisms. Recent studies have found the class of drugs called PARP inhibitors to selectively target ovarian cancers with homologous recombination deficiency. There are eight PARP inhibitors in various phases of clinical development with four being actively studied in phase III trials in ovarian cancer. In December 2014, the first-in-human PARP inhibitor olaparib was approved for ovarian cancer patients with two different clinical indications in Europe and the United States.
Summary:
Ovarian cancer has become a model for the successful translation of targeted therapy against DNA repair deficiencies in cancer.
Insights
Poly (ADP-ribose) polymerase (PARP) inhibitors are a successful targeted therapy for ovarian cancers with DNA repair deficiencies. This approach is revolutionizing ovarian cancer treatment strategies.
Area of Science:
- Oncology
- Genetics
- Pharmacology
Background:
- Ovarian cancers often exhibit DNA repair deficiencies, particularly in homologous recombination.
- These deficiencies can arise from germline mutations (e.g., BRCA1, BRCA2) or somatic alterations.
Purpose of the Study:
- To review the role of DNA repair deficiencies in ovarian cancer.
- To discuss poly (ADP-ribose) polymerase (PARP) inhibition as a targeted therapeutic strategy.
Main Methods:
- Review of recent clinical studies and trials on PARP inhibitors in ovarian cancer.
- Analysis of drug development phases and approvals for PARP inhibitors.
Main Results:
- PARP inhibitors selectively target ovarian cancers with homologous recombination deficiency.
- Eight PARP inhibitors are in clinical development, with four in Phase III trials.
- Olaparib received FDA and EMA approval in 2014 for specific ovarian cancer indications.
Conclusions:
- Ovarian cancer serves as a model for targeted therapy development against DNA repair defects.
- PARP inhibition represents a successful translation of understanding DNA repair to clinical treatment.
Related Concept Videos
01:38Nucleotide Excision Repair
Cells are regularly exposed to mutagens—factors in the environment that can damage DNA and generate mutations. UV radiation is one of the most common mutagens and is estimated to introduce a significant number of changes in DNA. These include bends or kinks in the structure, which can block DNA replication or transcription. If these errors are not fixed, the damage can cause mutations, which in turn can result in cancer or disease depending on which sequences are...
01:08Nucleotide Excision Repair
01:08Nucleotide Excision Repair
02:36DNA Damage can Stall the Cell Cycle
02:36DNA Damage Can Stall the Cell Cycle
01:54Base Excision Repair
The first step of...